SERTAD4

Across TCGA pan-cancer cohorts, SERTAD4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SERTAD4 data layer compared with 31 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SERTAD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SERTAD4 expression acts as an unfavorable survival marker.

LUSC, KIRP, and KIRC are the cancer types where SERTAD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.079	0.746	<.001	36	view →
KIRP	OS	Median	All	0.216	0.903	.002	15	view →
KIRC	OS	Median	All	0.182	0.811	.004	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
LUAD	OS	Median	II,III,IV	0.540	0.709	.026	4	view →
MESO	OS	Median	All	0.169	0.556	.043	3	view →
SKCM	OS	Median	All	0.157	0.343	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SERTAD4–LUSC (OS)

Open the LUSC breakdown →